Nephrolyx DNPx Digital Nephrology Basic Platform
Nephrolyx DNPx Digital Nephrology Basic Platform was developed in Germany by Nephrolyx Gmbh.
Content: DNPx – algorithmic software application
Stability: 1 year license
For Research Use Only
Additional Products:
Assay Background
Renal diseases stand as a significant health concern globally, ranking as the 10th leading cause of death and affecting approximately 10% of the world’s population, resulting in an alarming 1.3 million deaths annually as of 2019. In the United States alone, a staggering 37 million adults grapple with Chronic Kidney Disease (CKD), with an estimated 90% of cases remaining undiagnosed and untreated. The financial burden of treatment in the US is projected to soar beyond $48 billion annually, with kidney failure treatment consuming a notable 6.7% of the Medicare budget despite covering less than 1% of the population. A multitude of factors contribute to kidney disease, including prevalent conditions such as Diabetes, Hypertension, Heart disease/failure, Acute Kidney Injury, Nephrotoxicity (often resulting from cancer treatments), Glomerular diseases, Severe infections such as sepsis, Inherited conditions, and various other etiologies. Early detection and intervention play pivotal roles in halting or slowing the progression of kidney diseases. Monitoring renal function is typically conducted through the assessment of Glomerular Filtration Rate (GFR), serving as the primary marker for diagnosing, monitoring, and guiding treatment strategies for kidney ailments. Currently estimating GFP using SrCr and/or Cystatic C. Problems, subject to nonGFR determinants, up to 48 hour delay in reflecting GFR changes
Assay Principle
The true measurement of Glomerular Filtration Rate (mGFR) is based on the Iohexol-Plasma-Clearance. A defined amount of Iohexol is injected into the individual. The contrast agent is then eliminated from the bloodstream by the kidneys over time as logarithmic reduction of Iohexol concentration in the blood. Kinetic results obtained from this process provide crucial insights into GFR performance. The distribution of Iohexol throughout the body influences the accuracy of the measurements. A single sample taken at approximately 240 minutes post-injection, is the minimum requirement for assessment, a method known as “one-point kinetic.” Ideally, multiple samples are collected for a more comprehensive evaluation. These samples are obtained at intervals such as 120, 150, 180, and 300 minutes post-injection. The concentration of Iohexol in sera is measured. A logarithmic fit is applied to the data to determine the Area Under the Curve (AUC), with corrections using the Broechner Mortensen method for enhanced accuracy. The Jacobsen formula is employed to calculate GFR based on the collected data.
Related Products
Fetuin A (PTM) ELISA Assay Kit
Urine Creatinine Detection Kit
Creatinine Serum Detection Kit
Rapid Cystatin C ELISA Assay Kit